Skip to content
phase 3Weight Loss & Diabetes

Glucose-dependent Insulinotropic Polypeptide

Also known as: GIP, Gastric Inhibitory Polypeptide, Incretin

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino-acid incretin hormone secreted by enteroendocrine K-cells of the duodenum and jejunum in response to nutrient ingestion. Along with GLP-1, GIP accounts for the "incretin effect" — the observation that oral glucose produces a far greater insulin response than intravenous glucose. GIP is now a major therapeutic target: tirzepatide (Mounjaro/Zepbound), the first GIP/GLP-1 dual agonist, has achieved unprecedented ~22.5% weight loss in clinical trials, validating the additive metabolic benefits of combined incretin pathway activation.

3 cited references·5 researched benefits

Quick Answer

GIP is a 42-amino-acid incretin hormone released from intestinal K-cells after eating. It stimulates insulin secretion in a glucose-dependent manner and has direct effects on adipose tissue, bone, and brain. GIP is the "other incretin" alongside GLP-1, and combined GIP/GLP-1 receptor agonism (tirzepatide) achieves superior weight loss (~22.5%) and glycemic control compared to GLP-1 alone. GIP receptor targeting is central to next-generation obesity and diabetes therapeutics.

Key Facts

Mechanism
GIP is released from duodenal/jejunal K-cells within minutes of nutrient ingestion (especially fat and glucose). It binds the GIP receptor (GIPR), a class B GPCR on pancreatic beta cells, activating Gs-cAMP-PKA and Epac2 signaling to potentiate glucose-dependent insulin secretion (the incretin effect). GIP also promotes beta cell proliferation and survival. On adipocytes, GIP enhances lipogenesis, increases adipose tissue blood flow, and promotes triglyceride storage. On bone, GIP stimulates osteoblast activity and inhibits bone resorption (potential anti-osteoporotic effect). In the brain, GIPR activation in the hypothalamus modulates appetite. Paradoxically, both GIP receptor agonism (tirzepatide) and antagonism (AMG-133) show anti-obesity effects, suggesting context-dependent metabolic roles.
Research Status
phase 3
Half-Life
~5–7 minutes
Molecular Formula
C₂₂₅H₃₄₈N₆₀O₆₈S
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Incretin effect — responsible for approximately 50% of the incretin effect (enhanced insulin secretion after oral vs. IV glucose)strong
  • Enhanced weight loss via dual agonism — GIP/GLP-1 dual agonist tirzepatide achieves ~22.5% weight loss, surpassing GLP-1-only agentsstrong
  • Superior glycemic control — tirzepatide (GIP/GLP-1) achieves HbA1c reductions of 2.0–2.6%, exceeding semaglutide in head-to-head trials (SURPASS-2)strong
  • Bone protective effects — GIP stimulates osteoblast differentiation and inhibits osteoclast activity, reducing fracture risk in preclinical modelsmoderate
  • Beta cell preservation — GIP receptor activation promotes beta cell proliferation and reduces apoptosis in preclinical diabetes modelspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous infusion (research)1–4 pmol/kg/minContinuous infusion during glucose clamp studiesUsed in clinical research to study the incretin effect and beta cell function. Not available as a standalone therapeutic product. The rapid DPP-4 degradation (half-life ~5–7 minutes) makes native GIP impractical for therapy.
Subcutaneous injection (as tirzepatide — GIP/GLP-1 dual agonist)2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mgOnce weeklyTirzepatide (Mounjaro/Zepbound) is the first approved GIP/GLP-1 dual agonist. The GIP component is the primary driver of GIPR activation. Dose escalation occurs every 4 weeks to minimize GI side effects.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • GI side effects (in dual agonists) — nausea, vomiting, and diarrhea are common with GIP/GLP-1 agonists like tirzepatide, though the GIP component may actually reduce nauseacommon
  • Potential adipose tissue effects — GIP promotes lipogenesis; the metabolic consequences of chronic GIPR agonism on adiposity require long-term studycommon
  • Thyroid C-cell concerns — preclinical rodent studies with GIPR agonists warrant monitoring, though human relevance is uncertainrare
  • Hypoglycemia risk — incretin-mediated insulin secretion is glucose-dependent, making hypoglycemia uncommon as monotherapy but possible with concurrent sulfonylureas or insulinrare

Frequently Asked Questions

What is the incretin effect and why does GIP matter?
The incretin effect is the observation that oral glucose stimulates 2–3× more insulin secretion than the same amount of glucose given intravenously. This is because gut hormones (incretins) released during eating amplify the insulin response. GIP and GLP-1 are the two incretin hormones, together accounting for 50–70% of the total insulin response to a meal. GIP contributes approximately 50% of the incretin effect in healthy individuals. In type 2 diabetes, the incretin effect is severely diminished, which is why incretin-based therapies (GLP-1 RAs, GIP/GLP-1 dual agonists) are so effective.
Why does both GIP receptor agonism AND antagonism promote weight loss?
This is one of the most puzzling questions in metabolic pharmacology. Tirzepatide (GIP receptor agonist + GLP-1 RA) produces ~22.5% weight loss, while AMG-133 (GIP receptor antagonist + GLP-1 RA) also shows promising weight loss in early trials. The leading hypothesis is that in the context of GLP-1 receptor co-activation, GIP receptor agonism reduces nausea (improving tolerability of higher GLP-1 doses) and has central appetite effects, while GIP antagonism blocks GIP-mediated fat storage in adipocytes. Both approaches may ultimately converge on similar net energy balance effects through different mechanisms.
How does tirzepatide use GIP to outperform semaglutide?
In the SURPASS-2 head-to-head trial, tirzepatide (15 mg) achieved 2.46% HbA1c reduction vs. semaglutide (1 mg) at 1.86%, and 13.1% weight loss vs. 6.7%. The GIP component adds several mechanisms: (1) additional incretin-mediated insulin secretion via GIPR on beta cells; (2) central appetite suppression through hypothalamic GIPR; (3) possible reduction in GLP-1-mediated nausea, allowing higher effective GLP-1 dosing; and (4) improved adipose tissue metabolism. The dual pathway creates complementary, synergistic effects beyond what GLP-1 alone achieves.
Why was GIP previously called "gastric inhibitory polypeptide"?
GIP was originally named "gastric inhibitory polypeptide" in 1971 because it was found to inhibit gastric acid secretion at supraphysiological doses. However, subsequent research showed this was not its primary physiological role. When its potent insulinotropic (insulin-stimulating) effect was discovered, the name was reinterpreted as "glucose-dependent insulinotropic polypeptide" while keeping the same abbreviation. The new name accurately reflects its main function — enhancing insulin secretion in response to glucose and nutrients.

References

  1. 1
    The biology of incretin hormones (GIP and GLP-1): a comprehensive review(2013)PubMed ↗
  2. 2
    GIP receptor agonism and antagonism: metabolic implications for obesity and diabetes(2017)PubMed ↗
  3. 3
    Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)(2021)PubMed ↗

Latest Research

Last updated: 2026-02-19